Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926409 | 0.85 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CTSLCTSB | |
| SCHEMBL1689401 | 0.83 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CTSLCTSB | |
| SCHEMBL6445026 | 0.83 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CTSLCTSB | |
| SCHEMBL336495 | 0.83 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CTSLCTSB | |
| SCHEMBL24106653 | 0.81 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CTSLCTSB | |
| SCHEMBL8518995 | 0.81 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CTSLCTSB | |
| Ammonia Solution, Strong SCHEMBL29062672 | 0.81 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CTSLCTSB | |
| SCHEMBL3187773 | 0.81 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CTSLCTSB | |
| SCHEMBL13451748 | 0.81 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CTSLCTSB | |
| SCHEMBL19544584 | 0.80 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11236094-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors | CSPC ZHONGQI PHARMACEUTICALL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20220024908-A1 | PREPARATION METHOD FOR DEUTERATED MACROCYCLIC COMPOUND | SHENZHEN TARGETRX, INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200207773-A1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
| CN-111233833-A | Preparation method of deuterated macrocyclic compound | 深圳市塔吉瑞生物医药有限公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-2822953-B9 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2822953-B9 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9663472-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013132376-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013132376-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2012030907-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-08 | — | — | WO | disclosed |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | HDAC6 399/4885HDAC1 243/4885HDAC2 237/4885 |
| US-11236094-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors | FGFR1, FGFR2, FGFR4 | HDAC6 433/4885HDAC1 136/4885HDAC2 307/4885 |
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, EML4 | HDAC6 1212/4885HDAC1 2071/4885HDAC2 3453/4885 |
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | HDAC6 1243/4885HDAC1 1631/4885HDAC2 3318/4885 |
| US-20220024908-A1 | PREPARATION METHOD FOR DEUTERATED MACROCYCLIC COMPOUND | CTRC, GCG, SBDS | HDAC6 1886/4885HDAC1 1581/4885HDAC2 1657/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | HDAC6 494/4885HDAC1 392/4885HDAC2 1048/4885 |
| US-20200207773-A1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | FGFR1, FGFR2, FGFR3 | HDAC6 514/4885HDAC1 494/4885HDAC2 994/4885 |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | HDAC6 1624/4885HDAC1 2697/4885HDAC2 2383/4885 |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | HDAC6 1624/4885HDAC1 2697/4885HDAC2 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.